Click for best price

COVID19 Recombinant Protein Vaccine Market Size, Share 2023

Preparation and immunogenicity and immunoprotection of Hib polysaccharide conjugate vaccine based on pneumococcal surface adhesive (PsaA).Methods PsaA gene recombinant protein (rPsaA) was prepared by genetic engineering, and then conjugated with Hib polysaccharide by amide condensation.The 3-week-old mice were immunized with this vaccine, and mice were inoculated with tetanus toxoid and haemophilus influenzae type B (Hib) polysaccharide conjugate vaccine (hib-tt) as controls and phosphate buffer (PBS) as blank controls.

This report contains market size and forecasts of COVID-19 Recombinant Protein Vaccine in Global, including the following market information:

Global COVID-19 Recombinant Protein Vaccine Market Size 2024-2030, ($ millions)

The global COVID-19 Recombinant Protein Vaccine market is projected to reach US$ million by 2029.

We surveyed the COVID-19 Recombinant Protein Vaccine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global COVID-19 Recombinant Protein Vaccine Market, by Type, 2024-2030 ($ millions)

Global COVID-19 Recombinant Protein Vaccine Market Segment Percentages, by Type

Being Developed

Preclinical

Clinical I

Clinical II

Global COVID-19 Recombinant Protein Vaccine Market, by Application, 2024-2030 ($ millions)

Global COVID-19 Recombinant Protein Vaccine Market Segment Percentages, by Application

Pharmaceutical And Biotechnology Companies

Hospital

Academic And Research Organizations

Other

Global COVID-19 Recombinant Protein Vaccine Market, By Region and Country, 2024-2030 ($ Millions)

Global COVID-19 Recombinant Protein Vaccine Market Segment Percentages, by region and country

United States

Europe

Asia

China

Rest of World

Competitor Analysis

The report also provides analysis of leading market participants including:

Further, the report presents profiles of competitors in the market, key players include:

GSK

Johnson & Johnson

Sanofi

Novavax

Pukang Biologic Technology

Clover Biopharmaceuticals

Suzhou Yuzhibo Biotechnology

Report Attributes	Report Details
Report Title	COVID-19 Recombinant Protein Vaccine Market, Global Outlook and Forecast 2023-2030
Historical Year	2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year	2022
Forecast Year	2030
Number of Pages	69 Pages
Customization Available	Yes, the report can be customized as per your need.

1 Introduction to Research & Analysis Reports
1.1 COVID-19 Recombinant Protein Vaccine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global COVID-19 Recombinant Protein Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global COVID-19 Recombinant Protein Vaccine Overall Market Size
2.1 Global COVID-19 Recombinant Protein Vaccine Market Size: 2023 VS 2030
2.2 Global COVID-19 Recombinant Protein Vaccine Market Size, Prospects & Forecasts: 2023-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Key COVID-19 Recombinant Protein Vaccine Players in Global Market
3.2 Global Companies COVID-19 Recombinant Protein Vaccine Product & Technology
4 COVID-19 Recombinant Protein Vaccine Companies Profiles
4.1 GSK
4.1.1 GSK Company Summary
4.1.2 GSK Business Overview
4.1.3 GSK COVID-19 Recombinant Protein Vaccine Product Offerings & Technology
4.1.4 GSK COVID-19 Recombinant Protein Vaccine R&D, and Plans
4.2 Johnson & Johnson
4.2.1 Johnson & Johnson Company Summary
4.2.2 Johnson & Johnson Business Overview
4.2.3 Johnson & Johnson COVID-19 Recombinant Protein Vaccine Product Offerings & Technology
4.2.4 Johnson & Johnson COVID-19 Recombinant Protein Vaccine R&D, and Plans
4.3 Sanofi
4.3.1 Sanofi Company Summary
4.3.2 Sanofi Business Overview
4.3.3 Sanofi COVID-19 Recombinant Protein Vaccine Product Offerings & Technology
4.3.4 Sanofi COVID-19 Recombinant Protein Vaccine R&D, and Plans
4.4 Novavax
4.4.1 Novavax Company Summary
4.4.2 Novavax Business Overview
4.4.3 Novavax COVID-19 Recombinant Protein Vaccine Product Offerings & Technology
4.4.4 Novavax COVID-19 Recombinant Protein Vaccine R&D, and Plans
4.5 Pukang Biologic Technology
4.5.1 Pukang Biologic Technology Company Summary
4.5.2 Pukang Biologic Technology Business Overview
4.5.3 Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Product Offerings & Technology
4.5.4 Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine R&D, and Plans
4.6 Clover Biopharmaceuticals
4.6.1 Clover Biopharmaceuticals Company Summary
4.6.2 Clover Biopharmaceuticals Business Overview
4.6.3 Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Product Offerings & Technology
4.6.4 Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine R&D, and Plans
4.7 Suzhou Yuzhibo Biotechnology
4.7.1 Suzhou Yuzhibo Biotechnology Company Summary
4.7.2 Suzhou Yuzhibo Biotechnology Business Overview
4.7.3 Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Product Offerings & Technology
4.7.4 Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine R&D, and Plans
5 Sights by Region
5.1 By Region - Global COVID-19 Recombinant Protein Vaccine Market Size, 2024 & 2030
5.2 By Region - Global COVID-19 Recombinant Protein Vaccine Revenue, (2024-2030)
5.3 United States
5.3.1 Key Players of COVID-19 Recombinant Protein Vaccine in United States
5.3.2 United States COVID-19 Recombinant Protein Vaccine Development Current Situation and Forecast
5.4 Europe
5.4.1 Key Players of COVID-19 Recombinant Protein Vaccine in Europe
5.4.2 Europe COVID-19 Recombinant Protein Vaccine Development Current Situation and Forecast
5.5 China
5.5.1 Key Players of COVID-19 Recombinant Protein Vaccine in China
5.5.2 China COVID-19 Recombinant Protein Vaccine Development Current Situation and Forecast
5.6 Rest of World
6 Sights by Product
6.1 By Type - Global COVID-19 Recombinant Protein Vaccine Market Size Markets, 2024 & 2030
6.2 Being Developed
6.3 Preclinical
6.4 Clinical I
6.5 Clinical II
7 Sights by Application
7.1 By Application - Global COVID-19 Recombinant Protein Vaccine Market Size, 2024 & 2030
7.2 Pharmaceutical And Biotechnology Companies
7.3 Hospital
7.4 Academic And Research Organizations
7.5 Other
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

LIST OF TABLES & FIGURES

List of Tables
Table 1. COVID-19 Recombinant Protein Vaccine Market Opportunities & Trends in Global Market
Table 2. COVID-19 Recombinant Protein Vaccine Market Drivers in Global Market
Table 3. COVID-19 Recombinant Protein Vaccine Market Restraints in Global Market
Table 4. Key Players of COVID-19 Recombinant Protein Vaccine in Global Market
Table 5. Global Companies COVID-19 Recombinant Protein Vaccine Product & Technology
Table 6. GSK Company Summary
Table 7. GSK COVID-19 Recombinant Protein Vaccine Product Offerings
Table 8. Johnson & Johnson Company Summary
Table 9. Johnson & Johnson COVID-19 Recombinant Protein Vaccine Product Offerings
Table 10. Sanofi Company Summary
Table 11. Sanofi COVID-19 Recombinant Protein Vaccine Product Offerings
Table 12. Novavax Company Summary
Table 13. Novavax COVID-19 Recombinant Protein Vaccine Product Offerings
Table 14. Pukang Biologic Technology Company Summary
Table 15. Pukang Biologic Technology COVID-19 Recombinant Protein Vaccine Product Offerings
Table 16. Clover Biopharmaceuticals Company Summary
Table 17. Clover Biopharmaceuticals COVID-19 Recombinant Protein Vaccine Product Offerings
Table 18. Suzhou Yuzhibo Biotechnology Company Summary
Table 19. Suzhou Yuzhibo Biotechnology COVID-19 Recombinant Protein Vaccine Product Offerings
Table 20. By Region? Global COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2024 & 2030
Table 21. By Region - Global COVID-19 Recombinant Protein Vaccine Revenue, (US$, Mn), 2024-2030
Table 22. By Type ? Global COVID-19 Recombinant Protein Vaccine Market Size, (US$, Mn), 2024 & 2030
Table 23. By Application? Global COVID-19 Recombinant Protein Vaccine Market Size, (US$, Mn), 2024 & 2030
List of Figures
Figure 1. COVID-19 Recombinant Protein Vaccine Segment by Type in 2030
Figure 2. COVID-19 Recombinant Protein Vaccine Segment by Application in 2030
Figure 3. Global COVID-19 Recombinant Protein Vaccine Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global COVID-19 Recombinant Protein Vaccine Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global COVID-19 Recombinant Protein Vaccine Revenue, 2017-2028 (US$, Mn)
Figure 7. By Region - Global COVID-19 Recombinant Protein Vaccine Revenue Market Share, 2024-2030
Figure 8. By Type - Global COVID-19 Recombinant Protein Vaccine Revenue Market Share, 2024-2030
Figure 9. By Application - Global COVID-19 Recombinant Protein Vaccine Revenue Market Share, 2024-2030

DOWNLOAD SAMPLE

Download
Free Sample

Request
Customization

Check
Discount

REPORT PURCHASE OPTIONS

Single User Price : $3095

Multi User Price : $4024

Enterprise Price : $4643

---- OR ----

Frequently Asked Questions ?

Delivery Time

Upto 24 hrs - Working days
Upto 48 hrs max - Weekends and public holidays

User License

Single User License
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

Multi user License
A license granted to multiple users.

Site License
A license granted to a single business site/establishment.

Corporate License, Global License
A license granted to all employees within organisation access to the product.

Payment Options

Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer

Report Delivery

Email
Hard Copy

Our Key Features

Data Accuracy and Reliability
Data Security
Customized Research
Trustworthy
Competitive Offerings

COVID-19 Recombinant Protein Vaccine Market, Global Outlook and Forecast 2023-2030